Therefore, we have evidences to support the hypothesis that the marked reduction of CD39+CD73+ B cells, together with the impaired expression of CD73 in T cells and the lack of other nucleotidases in the blood, lead to the lower concentrations of plasmatic ADO in COVID-19 patients and might exacerbate innate immune activation. The gene discussed is NT5E; the disease is COVID-19.